Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $70.79, for a total transaction of $35,395.00. Following the transaction, the vice president directly owned 73,924 shares of the company’s stock, valued at approximately $5,233,079.96. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $75.48, for a total value of $37,740.00.
• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total value of $40,920.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded up $0.21 during mid-day trading on Monday, hitting $70.40. The stock had a trading volume of 357,649 shares, compared to its average volume of 331,768. ANI Pharmaceuticals, Inc. has a fifty-two week low of $69.58 and a fifty-two week high of $99.39. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.62 billion, a PE ratio of 15.17 and a beta of 0.45. The company’s fifty day simple moving average is $76.97 and its two-hundred day simple moving average is $78.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The firm’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ANIP. Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price target on the stock. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Guggenheim dropped their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.57.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth $28,000. Hantz Financial Services Inc. raised its holdings in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the period. Persistent Asset Partners Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $76,000. State of Wyoming bought a new stake in ANI Pharmaceuticals during the second quarter valued at about $86,000. Finally, Kingdom Financial Group LLC. acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $141,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.